Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone109

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone37

Views

Views
June 20257
July 202520
August 20251
September 20251
October 20252
November 20255
December 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States14
Brazil10
United Kingdom3
Mexico2
South Africa2
Kenya2
Argentina1
Ecuador1
Paraguay1
Turkey1
 

Top cities views

Views
São Paulo2
Albuquerque1
Ambato1
Atakum1
Cantagalo1
Cape Town1
Dallas1
Goiânia1
Huntingdon1
Itobi1